SRPT
$78.50
Sarepta Therapeutics
($4.69)
(5.64%)
SRPT
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($1.02)
Revenue:  $192.62 Mil
Wednesday
Feb 2
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SRPT reports earnings?
Beat
Meet
Miss

Where is SRPT's stock price going from here?
Up
Flat
Down
Stock chart of SRPT
Analysts
Summary of analysts' recommendations for SRPT
Score
Grade
Pivots
Resistance
$89.68
$86.53
$82.52

$79.37

Support
$75.36
$72.21
$68.20
Tweet
Growth
Description
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbPfizerInterCept